Core Viewpoint - Haleon plc (NYSE:HLN) is recognized as one of the best young stocks to buy and hold for 20 years, with a maintained Buy rating and a price target of p450.00 by Jefferies analyst David Hayes [1]. Group 1: Stock Performance and Growth - Despite recent setbacks, including weaker cold and flu product sales in fiscal Q4 2025, Haleon has shown strong growth of over 4% across its portfolio [2]. - The company is expected to face another headwind from the cold and flu season in fiscal Q1 2026, yet it is projected to achieve 4% like-for-like growth [4]. - If Haleon can increase its underlying growth to 5% and achieve 9% growth in emerging markets, its valuation will be well supported [4]. Group 2: Company Overview - Haleon, along with its subsidiaries, is involved in the research, development, manufacturing, and sale of various consumer healthcare products across multiple regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific [5].

Notice of 2026 Annual General Meeting The AGM will again be a virtual meeting, taking place at 3.00pm (BST) on Wednesday 29 April 2026. Shareholders are invited to join online. To access the Meeting visit: https://meetings.lumiconnect.com/100-379-080-545 This document is important and requires your immediate attention. If you are in any doubt about the action you should take in relation to this document, you should consult an independent financial advisor authorised under the Financial Services and Markets ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissi ...

Core Insights - Haleon is investing £65 million in a new oral health manufacturing plant in Shanghai to enhance its presence in China's gum health market, which is valued at approximately £860 million [1] - The company aims to expand its gum health brand parodontax to 30 cities in China by the end of 2027, targeting a rising middle class with increasing disposable income [1] - Haleon's investment reflects its long-term commitment to improving the health and wellbeing of Chinese consumers through locally tailored products and enhanced manufacturing capabilities [1] Investment and Expansion - The new manufacturing facility will support the expansion of Haleon's oral care portfolio, including global brands like Sensodyne and parodontax, into tier 2 and tier 3 cities in China [1] - Haleon plans to reach over 250 million people through its distribution strategy, which includes e-commerce platforms and retail pharmacies [1] - The investment is part of a broader strategy to respond quickly to evolving consumer preferences and accelerate innovation in the oral care category [1] Product Development - parodontax is the first clinically proven toothpaste in China targeting the root cause of bleeding gums, with a unique sensory profile adapted for local consumers [1] - Haleon's global R&D team collaborated with local scientists to modify the product's flavor and packaging to better appeal to Chinese consumers [1] - The company is focused on delivering high-quality, science-backed products that align with the growing demand for preventative oral care solutions [1] Strategic Priorities - China is identified as a strategic priority for Haleon, with the company aiming to combine global research expertise with local insights to enhance product offerings [1] - The new facility in Shanghai's Lingang New Area will enable Haleon to build a more agile and efficient supply chain, supporting its ambition to reach one billion more consumers by 2030 [1] - Haleon completed the acquisition of its TSKF joint venture in June 2025, further solidifying its position in China's consumer healthcare market [1]

Core Insights - Haleon is intensifying its expansion in China, focusing on second- and third-tier cities and customizing its gum-health products to local preferences, aiming to succeed where many Western brands have struggled [1] Company Strategy - Haleon is investing £65 million ($87 million) in a new oral-health factory in Shanghai to support its growth strategy in China [1] - The company aims to expand its Parodontax brand into over 30 cities by the end of 2027, addressing a significant consumer need as over 70% of Chinese consumers suffer from gum health issues [1][1] Market Context - China represents about 10% of Haleon's £11 billion business and nearly 13% of the $59 billion global oral-health market, which is projected to reach approximately $80 billion by 2031 [1] - Haleon's Sensodyne toothpaste is experiencing mid-teens growth, with around 11% of Chinese households using the brand, compared to local leader Yunnan Baiyao at 29.8% [1] Product Adaptation - The Parodontax brand was relaunched in China with modifications to suit local tastes, including a sweeter flavor, foamier texture, and glossier packaging, now available in 10,000 outlets across 19 cities [1][1] Competitive Landscape - Many Western companies, such as Starbucks and Nike, are scaling back their operations in China due to weak sales, while Haleon has taken a different approach by buying out the Chinese government from its local joint venture for approximately £700 million [1]

Core Findings - A study published in Nature Medicine indicates that taking Centrum Silver daily may slow biological aging markers in older adults [1] - The research is based on the COSMOS trial, which is the first large-scale randomized controlled trial examining the effects of daily multivitamins on biological aging [1][2] - The study found that participants taking Centrum Silver experienced a statistically significant slowing in all five epigenetic clocks, equating to approximately four months less biological aging over two years compared to the placebo group [1][2] Study Details - The COSMOS trial involved nearly 1,000 older adults, with participants randomized to receive either a daily multivitamin, cocoa extract, both, or a placebo [1] - The study specifically measured biological aging through five DNA-based epigenetic clocks, which assess changes in DNA that occur naturally with aging [1] - Results showed that individuals with accelerated biological aging at baseline benefited more from the multivitamin intervention [1][2] Implications for Centrum - The findings support the notion that Centrum Silver is a safe, accessible, and low-cost intervention that may contribute to healthy aging [1] - Centrum has a long-standing commitment to nutritional research, being the most clinically studied multivitamin brand globally [1] - The study reinforces the credibility and scientific rigor of Centrum's product offerings, particularly in relation to aging and overall health [1]

Group 1 - Haleon reported a total revenue of £11.03 billion for the full-year 2025, with the Oral Health sector achieving approximately 8% organic growth [2] - The company maintained or gained market share in 60% of its business segments, driven by productivity initiatives such as a 26% reduction in SKU complexity and optimized logistics [2] - Despite challenges in North America due to low consumer confidence and a weak cold and flu season, Haleon experienced strong growth in the EMEA, Latin America, and Asia-Pacific regions [1][5] Group 2 - For 2026, Haleon anticipates organic revenue growth to accelerate to between 3% and 5%, supported by a new operating model aimed at increasing agility [3] - The company has created a Chief Growth Officer role and restructured into six specific operating units to better capture regional opportunities [3] - Management plans to achieve high single-digit adjusted operating profit growth and has allocated £500 million for share buybacks in the upcoming year [3]

Core Viewpoint - Haleon PLC Sponsored ADR (HLN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Haleon PLC is expected to earn $0.54 per share for the fiscal year ending December 2026, with a 1.9% increase in the Zacks Consensus Estimate over the past three months [8]. Investment Implications - The upgrade to Zacks Rank 2 positions Haleon PLC in the top 20% of Zacks-covered stocks, suggesting potential for higher stock prices due to improved earnings outlook [10]. - Rising earnings estimates and the corresponding rating upgrade indicate an improvement in Haleon PLC's underlying business, which could lead to increased investor interest and stock appreciation [5].

Core Insights - Haleon plc reported Q4 2025 earnings with an EPS of $0.259, surpassing analyst expectations of $0.251, but revenue was approximately $7.52 billion, slightly below the forecast of $7.57 billion [1] Financial Performance - The company achieved an organic growth rate of 3% for the year, falling short of its medium-term target of 4-6%, primarily due to challenges in the North American market, which constitutes 35% of its revenues [2] - North America experienced a 0.4% decline in organic growth, influenced by cautious consumer behavior amid inflation and labor market concerns, particularly affecting discretionary categories like Smokers' Health and multivitamins [2] - Despite these challenges, Haleon reported double-digit profit growth and strong cash generation, indicating robust long-term prospects [2] Valuation Metrics - Haleon's price-to-earnings (P/E) ratio is approximately 14.47, reflecting the market's valuation of its earnings [3] - The price-to-sales ratio stands at about 2.10, indicating the company's market value relative to its sales [3] - The enterprise value to sales ratio is around 2.57, providing a comparison of the company's total value to its sales [3] - The enterprise value to operating cash flow ratio is approximately 37.62, highlighting cash flow generation relative to valuation [3] - The earnings yield is about 6.91%, offering insight into the return on investment [3] - Haleon maintains a moderate leverage level with a debt-to-equity ratio of 0.53 [3] - A current ratio of approximately 0.87 indicates the company's short-term liquidity position [3]

We recently published 10 Stocks Left Behind in a Roaring Market. Haleon plc (NYSE:HLN) was one of the worst performers on Wednesday. Haleon dropped its share prices by as much as 7.67 percent on Wednesday to close at $10.43 apiece after missing its revenue growth guidance last year. In an updated report, Haleon plc (NYSE:HLN) said that it incurred an organic revenue growth of 3 percent, missing its previous outlook of 3.5 percent, primarily dampened by a weakening US consumer environment, coupled with a ...